Del.icio.us
Google
Yahoo MyWeb
Facebook
GlobeImmune Overview
GlobeImmune is a biopharmaceutical company pioneering the discovery, development and manufacturing of potent, targeted molecular immunotherapies called Tarmogens for the treatment of cancer and infectious diseases. GI-5005, GlobeImmune’s lead product for the treatment of chronic hepatitis infection, completed enrollment in May 2008 of a multi-center, randomized Phase 2 study. This study...More»
GlobeImmune is a biopharmaceutical company pioneering the discovery, development and manufacturing of potent, targeted molecular immunotherapies called Tarmogens for the treatment of cancer and infectious diseases. GI-5005, GlobeImmune’s lead product for the treatment of chronic hepatitis infection, completed enrollment in May 2008 of a multi-center, randomized Phase 2 study. This study evaluated GI-5005 plus standard of card (pegylated interferon plus ribavirin) versus standard of care alone in 140 subjects. Additionally, GI-4000 for the treatment of Ras-mediated cancers, is currently being evaluated in mujltiple Phase 2 clinical trials including the treatment of resectable (early) pancreas cancer, NSCLC and locally advanced pancreas cancer.«Less
Key People
Board of Directors
Advisors
Funding
| Date | Type | Capital Amount | Post-Money Valuation | Investors |
|---|---|---|---|---|
| 09/2007 | Series C | 41.2M | Unknown |
Products
| Name: | GI-3000 |
| Product URL: | http://www.globeimmune.com/index.php?load=content&page_id=49 |
| Description: | The epidermal growth factor receptor (EGFR) is a key point in initiation of cell division in both normal and cancer cells. In a number of cancers, including non-small cell lung cancer (NSCLC) and glioblastoma (brain cancer), EGFR is either overexpressed or mutated, and these changes are believed to be key events in the formation and growth of numerous tumors. Using Tarmogens that target both normal and mutated EGFR, GlobeImmune has demonstrated prolonged survival, and in several cases, complete tumor remission, in an animal model of brain cancer in which the tumor cells express human EGFR. |
| Screenshots: |
|
Competitors
Profile
OpinionsRelated Companies
User Opinions
Bulls vs. Bears (0)
| Bullish Opinions (0) | ||||
|---|---|---|---|---|
| Be the first to tell us why they are destined to succeed | ||||
| Bearish Opinions (0) | ||||
|---|---|---|---|---|
| Be the first to tell us why they are destined to stumble. | ||||
Discussions (0)
Start a New Discussion
Opinion Poll
View All Opinions »
Similar Companies
View All Similar »Web Metrics
View All Web Metrics »
| Alexa Rank: | n/a |  |
n/a |
| Yahoo Search Results: | n/a | ||
GlobeImmune on Twitter
Twitter Search »Discussions
View All Discussions »There are no discussions right now.
Recent Contributors
There are no recent contributors to this company.
Related Jobs
loading...